Ernexa Stock Price, News & Analysis

Cellipont Bioservices and Ernexa Therapeutics (Nasdaq: ERNA) announced a collaboration on Oct 29, 2025 to advance ERNA-101, Ernexa's lead allogeneic iMSC cell therapy for ovarian cancer, into clinical manufacturing and trials. The agreement covers Engineering, Differentiation, and Production (EDP) activities and cGMP development and scale-up of the ERNA-101 manufacturing process.

ERNA-101 is an off-the-shelf iMSC therapy designed to reprogram immunologically "cold" tumors to "hot" ones; preclinical data were presented at AACR and ASCO. The partnership targets translating preclinical promise into a clinically viable therapy.

Ernexa Therapeutics (Nasdaq: ERNA), a company focused on developing cell therapies for cancer and autoimmune diseases, will present at the Cell & Gene Meeting on the Mesa on October 7, 2025 in Phoenix, Arizona.

The company will showcase its pipeline, including ERNA-101, a cell therapy targeting ovarian cancer, and ERNA-201 for autoimmune disease treatment. Both therapies utilize Ernexa's proprietary synthetic, allogeneic induced mesenchymal stem cell (iMSC) technology to create off-the-shelf treatments.

Recently, Ernexa presented new data on ERNA-101 at the AACR Special Conference, demonstrating how their gene-modified iPSC-derived MSC technology improves the immune microenvironment in high-grade serous ovarian cancer.

Ernexa Therapeutics (Nasdaq: ERNA), a cell therapy company, announced that CEO Sanjeev Luther will participate in a panel discussion at the 5th Annual iPSC Drug Development Summit on October 1, 2025, in Boston.

The company is developing engineered induced mesenchymal stem cells (iMSC) therapies, including ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease. Ernexa's approach focuses on creating scalable, allogeneic, off-the-shelf treatments without requiring patient-specific cell harvesting. The company recently presented data on ERNA-101's ability to restore a "hot" immune microenvironment in high-grade serous ovarian cancer at an AACR Special Conference.

Ernexa Therapeutics (Nasdaq: ERNA) announced it will present new preclinical data for its lead cell therapy candidate ERNA-101 at the AACR Special Conference in Cancer Research on September 20, 2025. The presentation will focus on ERNA-101's ability to reprogram the ovarian tumor microenvironment.

The oral presentation, led by Dr. Michael Andreeff from MD Anderson Cancer Center, will showcase how ERNA-101, an off-the-shelf cell therapy using engineered induced pluripotent stem cells (iPSCs), can potentially activate the immune system to target cancer cells. The therapy demonstrates promise in restoring immune activity in difficult-to-treat ovarian tumors.

Ernexa Therapeutics (NASDAQ: ERNA), a cell therapy company focusing on cancer and autoimmune diseases, reported significant operational improvements for H1 2025. The company achieved a 51% reduction in operating loss to $5.2 million, down from $10.7 million in H1 2024. Total operating expenses decreased by 51% to $5.2 million, with general and administrative expenses dropping 66% to $2.8 million.

The company is advancing two key products: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease, both utilizing synthetic allogeneic induced mesenchymal stem cells (iMSCs) for off-the-shelf treatment. Lease expenses saw a dramatic 97% reduction to $0.1 million, primarily due to a sublease termination.

Ernexa Therapeutics (Nasdaq: ERNA), a biotechnology company focused on developing novel cell therapies, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.

The company's leadership will showcase their proprietary iMSC platform and two lead programs: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease treatment. The presentation will highlight their development of scalable, off-the-shelf cell therapies, with ERNA-101 expected to enter clinical trials by 2026.

Ernexa Therapeutics (Nasdaq: ERNA), a biotechnology company focused on cell therapies for cancer and autoimmune diseases, has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company received formal notice from Nasdaq on July 1, 2025, confirming its continued listing status.

CEO Sanjeev Luther reaffirmed the company's commitment to advancing their pipeline, with plans to initiate their first clinical trial in early 2026. The company's focus remains on developing engineered cell therapies for ovarian cancer and autoimmune disease patients.

Ernexa Therapeutics (Nasdaq: ERNA) announced the expansion of its Scientific Advisory Board into a combined Scientific and Medical Advisory Board as it prepares for clinical trials in ovarian cancer and autoimmune disease. The company has appointed two distinguished physicians: Dr. Amir Jazaeri from MD Anderson Cancer Center, who will guide the ovarian cancer program, and Dr. Anna Jonsson from the University of Colorado, who will lead translational strategy for the autoimmune pipeline.

This strategic expansion follows Ernexa's recently strengthened financial position and marks its transition from research to clinical-stage development. The enhanced advisory board will support the company's scientific and clinical strategy as it advances its first oncology and autoimmune programs toward IND-enabling studies.

Ernexa Therapeutics (Nasdaq: ERNA), a company developing cell therapies for cancer and autoimmune diseases, has completed the second closing of its securities purchase agreement, raising $6.0 million in gross proceeds through the issuance of 3,181,145 shares and 622,134 prefunded warrants.

Combined with the initial closing of $1.1 million in April 2025, total gross proceeds reach $7.1 million. The financing, approved by stockholders at the 2025 Annual Meeting, will support working capital needs and debt repayment. A remaining subscription amount of $190,248 for 121,255 shares is pending. The company recently implemented a 1-for-15 reverse stock split on June 12, 2025.